Phase 1 N=34 Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders
Hepatitis B
Primary: Subjects With Local and/or General Adverse Events Irrespective of Severity — 8; 9; 7; 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=17 Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy
Leukaemia, Myelocytic, Acute
Primary: Number of Patients With Severe Toxicities — 1; 0 Participants
Phase 1 N=16 A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
Moderate Hepatic Impairment · Normal Hepatic Function
Primary: Number of Participants With Post-baseline Clinically Significant Findings in Physical Examinations — 0; 0 participants
Phase 1 N=40 Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine
Influenza
Primary: Adverse Events by Severity — 20; 8; 25; 8 Participants
Phase 1 N=18 Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
Renal Cell Carcinoma · Kidney Neoplasm · Renal Cancer
Primary: Number of Patients With Treatment-emergent Adverse Events — 3; 3; 6; 3 Participants
Phase 1 N=22 Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)
Hepatitis C Infection
Primary: Maximum log10 HCV Ribonucleic Acid (RNA) Change From Baseline — 2.84; 3.03; 3.36; 1.81 log10 IU/mL
Phase 1 N=13 E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) and Recommended Dose (RD) — 9 ug/kg/day
Phase 1 N=60 A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers
Asthma · Healthy Subjects or Volunteers
Primary: Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]) — 1426.47; 1243.28; 1251.63; 897.02 day*mcg/mL
Phase 1 N=102 Bivalent Norovirus Vaccine Study
Gastroenteritis
Primary: Number of Participants With Solicited Local Adverse Events (AEs) Post Dose 1 — 4; 5; 6; 5 participants
Phase 1 N=23 Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Solid Tumor · Kidney Cancer
Primary: Maximum Tolerated Dose (MTD) [Phase I Dose Finding] — 400 mg
Phase 1 N=8 A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
Carcinoma, Hepatocellular
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 4 Participants
Phase 1 N=24 Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function
Infections, Bacterial
Primary: Area Under the Plasma Concentration Time Curve (AUC) From Hour 0 to Infinity (AUC[0-inf]) of Gepotidacin for Part 1 — 14838; 22367; 28545 Nanogram*hour per milliliter
Phase 1 N=72 Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C
Healthy Volunteer
Primary: Cmax for Lomitapide — 0.570; 0.436; 1.70; 1.01 ng/mL
Phase 1 N=50 Staccato Loxapine Single Dose PK
Schizophrenia
Primary: Tmax — 12.6; 2.15; 2.87; 2.13 minutes
Phase 1 N=43 A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer
Hormone Treatment-naïve Participants With Prostate Cancer
Primary: Part A: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants